Morgan Stanley Reaffirms Equal Weight Rating for Ultragenyx Pharmaceutical Inc. (RARE)

Morgan Stanley reaffirmed their equal weight rating on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a research report sent to investors on Friday, October 6th. Morgan Stanley currently has a $71.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $69.00.

Other research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a neutral rating and set a $75.00 price target (up previously from $72.00) on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, August 8th. Jefferies Group LLC reaffirmed a hold rating and set a $68.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 14th. Evercore ISI initiated coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, August 16th. They set an in-line rating and a $63.00 price target for the company. Stifel Nicolaus reaffirmed a buy rating and set a $85.00 price target (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. Finally, Canaccord Genuity reissued a buy rating and issued a $83.00 target price (down previously from $98.00) on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $71.94.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 53.46 on Friday. The firm has a 50-day moving average of $53.62 and a 200 day moving average of $59.53. The company’s market capitalization is $2.27 billion. Ultragenyx Pharmaceutical has a 52-week low of $49.56 and a 52-week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the consensus estimate of ($1.73) by $0.01. During the same quarter in the previous year, the business earned ($1.46) EPS. Equities analysts predict that Ultragenyx Pharmaceutical will post ($7.14) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Reaffirms Equal Weight Rating for Ultragenyx Pharmaceutical Inc. (RARE)” was published by BBNS and is the property of of BBNS. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://baseballnewssource.com/markets/ultragenyx-pharmaceutical-inc-rare-earns-equal-weight-rating-from-morgan-stanley/1700853.html.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis bought 7,500 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, August 28th. The stock was bought at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the purchase, the chief executive officer now owns 430,569 shares in the company, valued at approximately $22,613,483.88. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 9.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Sei Investments Co. acquired a new stake in Ultragenyx Pharmaceutical in the second quarter worth $125,000. Pacer Advisors Inc. increased its position in Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 560 shares during the period. Strs Ohio increased its position in Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 300 shares during the period. Tocqueville Asset Management L.P. increased its position in Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares during the period. Finally, Kazazian Asset Management LLC acquired a new stake in Ultragenyx Pharmaceutical in the second quarter worth $213,000. 96.07% of the stock is currently owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.